中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.013 seconds)

    NOVEL SYNTHETIC C-GLYCOLIPIDS, THEIR SYNTHESIS AND USE TO TREAT INFECTIONS, CANCER AND AUTOIMMUNE DISEASES
    3.
    发明申请
    NOVEL SYNTHETIC C-GLYCOLIPIDS, THEIR SYNTHESIS AND USE TO TREAT INFECTIONS, CANCER AND AUTOIMMUNE DISEASES 审中-公开
    新型合成C-GLYCOLIPIDS，它们的合成和用途治疗感染，癌症和自发性疾病

    公开(公告)号：WO2005102049A1

    公开(公告)日：2005-11-03

    申请号：PCT/US2005/010889

    申请日：2005-03-31

    Applicant: NEW YORK UNIVERSITY ,  THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK ,  TSUJI, Moriya ,  FRANCK, Richard ,  CHEN, Guangwu

    Inventor： TSUJI, Moriya ,  FRANCK, Richard ,  CHEN, Guangwu

    IPC: A01N43/04

    CPC classification number: C07H7/02 ,  C07D309/10 ,  C07H13/00

    Abstract: The invention is directed to novel compounds of formulae (I), (II) and (III): wherein X is O or NH; R 3 is OH or a monosaccharide and R 4 is hydrogen, or R 3 is hydrogen and R 4 is OH or a monosaccharide; R 5 is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can be used to make these novel compounds.

    Abstract translation: 本发明涉及式（I），（II）和（III）的新化合物：其中X是O或NH; R 3是OH或单糖，R 4是氢，或R 3是氢，R 4是OH或单糖; R 5是氢或单糖; 及其药学上可接受的盐或酯。 本发明还涉及直接用作免疫佐剂的化合物用于治疗癌症，感染性疾病和自身免疫性疾病的用途。 本发明还涉及可用于制备这些新化合物的中间体的合成。

    MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES
    5.
    发明申请
    MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES 审中-公开
    免疫原性疟原虫环孢菌素蛋白表位修饰重组腺病毒

    公开(公告)号：WO2011022002A1

    公开(公告)日：2011-02-24

    申请号：PCT/US2009/054212

    申请日：2009-08-18

    Applicant: THE ROCKEFELLER UNIVERSITY ,  SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

    Inventor： SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

    IPC: C12N15/00 ,  A61K39/015

    CPC classification number: A61K39/015 ,  A61K2039/5256 ,  A61K2039/55577 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/861 ,  C12N2710/10322 ,  C12N2710/10341 ,  C12N2710/10343 ,  Y02A50/412

    Abstract: The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments. Further embodiments include a method of treating, preventing, or diagnosing malaria, comprising administering a therapeutic amount of the pharmaceutical composition or malaria vaccine composition in accordance with the above embodiment.

    Abstract translation: 本公开涉及腺病毒蛋白质修饰以增强对重组腺病毒转基因的免疫应答并规避预先存在的抗腺病毒免疫性。 一些实施方案涉及源自重组腺病毒质粒载体的重组腺病毒，其中重组腺病毒质粒载体包含编码与异源启动子和修饰的衣壳或核心蛋白可操作连接的疟原虫环子孢子蛋白或其抗原部分的核苷酸序列 其中将疟原虫环子孢子的免疫原性表位插入或取代至少部分衣壳或核心蛋白。 其他实施方案涉及包含根据上述实施方案的重组腺病毒的药物组合物或疟疾疫苗组合物。 其他实施方案包括治疗，预防或诊断疟疾的方法，其包括施用治疗量的根据上述实施方案的药物组合物或疟疾疫苗组合物。

    MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES
    8.
    发明申请
    MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES 审中-公开
    重组腺病毒与免疫球蛋白环孢菌素蛋白抗体的修饰

    公开(公告)号：WO2011022522A1

    公开(公告)日：2011-02-24

    申请号：PCT/US2010/045952

    申请日：2010-08-18

    Applicant: SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

    Inventor： SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

    IPC: A61K39/015

    CPC classification number: A61K39/015 ,  A61K2039/5256 ,  A61K2039/55577 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/861 ,  C12N2710/10322 ,  C12N2710/10341 ,  C12N2710/10343 ,  Y02A50/412

    Abstract: The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments. Further embodiments include a method of treating, preventing, or diagnosing malaria, comprising administering a therapeutic amount of the pharmaceutical composition or malaria vaccine composition in accordance with the above embodiment.

    Abstract translation: 本公开涉及腺病毒蛋白质修饰以增强对重组腺病毒的转基因的免疫应答并且绕过预先存在的抗腺病毒免疫。 一些实施方案涉及源自重组腺病毒质粒载体的重组腺病毒，其中重组腺病毒质粒载体包含可操作地连接到异源启动子和修饰的衣壳或核心蛋白的编码疟原虫环子孢子蛋白或其抗原部分的核苷酸序列 其中将疟原虫周围子孢子的免疫原性表位插入或取代衣壳或核心蛋白的至少一部分。 其它实施方案涉及包含根据上述实施方案的重组腺病毒的药物组合物或疟疾疫苗组合物。 另外的实施方案包括治疗，预防或诊断疟疾的方法，包括施用治疗量的根据上述实施方案的药物组合物或疟疾疫苗组合物。

    MODIFICATION OF RECOMBINANT ADENOVIRUS CAPSID PROTEIN WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES
    10.
    发明申请
    MODIFICATION OF RECOMBINANT ADENOVIRUS CAPSID PROTEIN WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES 审中-公开
    重组腺病毒CAPSID蛋白与免疫原性环磷酰胺蛋白抗原蛋白的修饰

    公开(公告)号：WO2012023995A1

    公开(公告)日：2012-02-23

    申请号：PCT/US2011/025535

    申请日：2011-02-18

    Applicant: SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

    Inventor： SHIRATSUCHI, Takayuki ,  TSUJI, Moriya

    IPC: A61K39/015 ,  A61K48/00

    CPC classification number: A61K39/015 ,  A61K2039/55577 ,  C12N2710/10022 ,  C12N2710/10043 ,  Y02A50/412

    Abstract: The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre- existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, comprising a nucleotide sequence encoding a Plasmodium circumsporozoite protein gene, or antigenic portion thereof, operably linked to a heterologous promoter sequence; and a modified Hexon hypervariable region (HRV) sequence comprising an immunogenic B cell epitope sequence of a Plasmodium falciparum circumsporozoite protein that is inserted into or replaces at least part of the HRV sequence. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments. Further embodiments include a method of treating, preventing, or diagnosing malaria, comprising administering a therapeutic amount of the pharmaceutical composition or malaria vaccine composition in accordance with the above embodiment.

    Abstract translation: 本公开涉及腺病毒蛋白质修饰以增强对重组腺病毒的转基因的免疫应答并且绕过预先存在的抗腺病毒免疫。 一些实施方案涉及源自重组腺病毒质粒载体的重组腺病毒，其包含可操作地连接到异源启动子序列的编码疟原虫周围子孢子蛋白基因或其抗原部分的核苷酸序列; 和包含被插入或替代至少部分HRV序列的恶性疟原虫环子孢子蛋白质的免疫原性B细胞表位序列的修饰的Hexon高变区（HRV）序列。 其它实施方案涉及包含根据上述实施方案的重组腺病毒的药物组合物或疟疾疫苗组合物。 另外的实施方案包括治疗，预防或诊断疟疾的方法，包括施用治疗量的根据上述实施方案的药物组合物或疟疾疫苗组合物。

Patent Agency Ranking